NewAmsterdam reports FY2024 net loss $241.6M, cash $834M; EMA submission on track for 2H25

NewAmsterdam Pharma Co N.V.

2024-FY EPS reported -$2.56 revenue$45,563,000

Cash, cash equivalents and marketable securities totaled $834.2M at Dec 31, 2024, up from $340.5M.
Revenue of $45.6M (FY2023: $14.1M) driven by a clinical milestone and cost reimbursement.
Net loss widened to $241.6M from $176.9M; R&D spend fell to $151.4M while SG&A rose to $70.4M.
Phase 3 BROADWAY met primary endpoint with 33% LDL-C reduction; TANDEM FDC achieved 49% reduction; BROOKLYN showed 36% reduction.
EMA submission planned for 2H25 via partner Menarini; USPTO issued obicetrapib solid-form patent until July 2043.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.